medcann Pharma strengthens its presence in Spain with the aim of becoming a leading player in the country through the supply of cannabis genetics and large-scale collaborative R&D&I projects. Learn more about our expansion and growth plans in this interview with PlantaDoce, a Spanish media specialized in the health and pharma sector.
Semana Magazine highlights the award received by medcann Pharma for contributing to the agroeconomic development of Meta. In 2016, medcann Pharma established its Production and Operations Center in the municipality of Fuentedeoro (Meta) which today is one of the company’s Research and Development hubs on cannabis genetics.
Conversation with LatinPyme magazine about the cannabis industry in Colombia, the potential and opportunities with the new resolution 227 of 2022, and what is missing to continue consolidating the development and progress of our sector.
Our CEO´s interview with Cannabis News, about medcann’s evolution, the work currently carried out in Europe – through the group’s subsidiary in Spain – and plans for this 2022, aiming at becoming global benchmark in genetics for medical and scientific purposes.
The national medical cannabis industry continues to strengthen along with the different companies that make it up, including medcann Pharma, which has made genetics its core business. Read our CEO`s interview, Carlos Adolfo Guzmán, with the economic newspaper La República, about the company’s plans for 2022…
Our genetics – legal and traceable to origin – are already in Europe for cannabis cultivation and extraction operations, and research projects, of two important Spanish producers of the cannabis industry for therapeutic purposes. Thanks to our clients Canamedics Labs and Cannabasa Agro&Pharma for trusting and choosing us as strategic partners.
Read news in:
Our technical-scientific team works hand in hand with Fasplan, a technology-based spin-off company created in the Faculty of Pharmaceutical and Food Sciences of the University of Antioquia to carry out research, development and innovation projects in genetics improvement, and commercialization of new cannabis varieties and cultivars for medical and scientific purposes, through micropropagated plant material.
News and progress on this important alliance coming soon.
We chatted with Álvaro and Luis Comas, co-founders of Canamedics Labs, the first Catalonian company obtaining AEMPS authorization for growing cannabis with high levels of psychoactive components (THC) for research purposes. The start-up chose medcann Pharma as a strategic business partner.
“The relationship with medcann was established based in confidence, and then it was accompanied by the technical element and the quality of the genetics. Its management team in Spain, experience and portfolio of genetics – legal and traceable to origin – was fundamental at the time of choosing”.
Since it is foundation, medcann Pharma manifests and maintains a genuine and determined interest in contributing to the development and progress of the industry, through collaborative work with key players.
• Since 2021, cannabis breeder members of CIOPORA – International Community of Breeders of Asexually Reproduced Horticultural Plant Varieties, specialized in Plant Variety Protection (PVP): patents, breeders’ rights, and registered trademarks.
• Founding members of Asocolcanna – Colombian Association of Cannabis Industries in 2017.